Treatment of Acute Ischemic STroke With Edaravone Dexborneol II (TASTE-2)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1362 participants.

Also called NCT05249920

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,362 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05249920
Other papers using this trial's data
  • Edaravone dexborneol versus placebo on functional outcomes in patients with acute ischaemic stroke undergoing endovascular thrombectomy (TASTE-2): randomised controlled trial BMJ (Clinical research ed.), 2026-01-07 DOI, PubMed 41500725, PMC12776454 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05249920. Randomized; quadruple masking; primary purpose treatment. Start 2022-03-18 (actual); primary completion 2023-02-17 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Treatment of Acute Ischemic STroke With Edaravone Dexborneol II (TASTE-2)
Condition
Acute Ischemic Stroke
Condition
Mechanical Thrombectomy
Condition
Edaravone Dexborneol
Condition
Phase III
Intervention (Drug)
Edaravone Dexborneol Concentrated Solution for injection
Intervention (Drug)
Edaravone Dexborneol placebo
Lead sponsor
Beijing Tiantan Hospital (class: other)

Record details

Record id
cardio:ct-nct05249920
Content hash
9dd11e177256202a7a47b0e47ac0f23f05d861926dcf96c3f0ddf9a7b254fbb5